[US Stock Movement] Twist Bioscience sharply declined on October 7: ARK reduces holdings, high valuation, and sector weakness

Interpretation of Twist Bioscience’s Sharp Decline on October 7

Keywords: ARK reduction, high valuation, sector weakness

1. On October 6, 2026, a fund under Ark Investment sold about 90.7 thousand shares of Twist Bioscience, amounting to approximately 18 million USD, with institutional position adjustment increasing the stock supply.

2. As of October 7, 2026, the company’s cumulative gain for the year still reaches 388.68%, with a decline of 19.78% in the past 5 days. The share price has risen sharply while the company has not yet achieved sustained profitability, leading to high pressure for valuation correction and profit-taking.

3. On October 6, 2026, NeoGenomics and 10x Genomics fell by about 12% and 17.47% respectively, with the biotechnology and genomics sectors weakening simultaneously, dragging down Twist Bioscience due to sector-wide selling.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)